Neurocrine Biosciences stock draws support from strong Q2 figures

Published on 09/19/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neurocrine Biosciences stock opened at USD 146.23 on September 18, 2026, after reporting USD 2.85 EPS on July 31, 2026. Revenue rose 39.5 percent to USD 959.00 million.

NBIX, US64125C1099, Illustration mit AI erstellt.

Neurocrine Biosciences stock (ISIN US64125C1099) opened at USD 146.23 on September 18, 2026, after the company reported USD 2.85 in quarterly EPS on July 31, 2026. The latest trading snapshot also showed a market capitalization of USD 14.86 billion and a 52-week range of USD 122.14 to USD 186.12.

July 31 earnings still matter

According to MarketBeat, Neurocrine Biosciences reported USD 2.85 EPS for the quarter on July 31, 2026, topping the consensus estimate of USD 1.65 by USD 1.20. The same report said revenue reached USD 959.00 million, up 39.5 percent year over year from USD 1.65 EPS in the prior-year period.

That mix leaves one number in the spotlight for investors: the quarter delivered both a 20.91 percent net margin and a 22.43 percent return on equity, while analysts on the same page still expect USD 7.26 EPS for the current fiscal year. A first.

Analysts stay constructive

According to MarketBeat, the stock had a consensus rating of Moderate Buy and a consensus price target of USD 201.09 on September 19, 2026. The same feed also listed Morgan Stanley's price target at USD 183.00 on September 13, 2026, and Royal Bank of Canada's Outperform view on September 10, 2026.

Those targets sit above the latest close of USD 146.23 on September 18, 2026, with the MarketBeat page showing a daily decline of 3.69 percent and extended trading at USD 146.57. The gap to the consensus target is USD 54.86.

Chart and cash return

MarketBeat's latest quote table put NBIX at a market capitalization of USD 14.86 billion, a 50-day moving average of USD 161.81 and a 200-day moving average of USD 151.96 on September 19, 2026. The 52-week low remained USD 122.14, and the 52-week high stood at USD 186.12.